Skip to content

The CAR T-Cell Race

Tumor-targeting T-cell therapies are generating remarkable remissions in hard-to-beat cancers—and attracting millions of dollars of investment along the way. By Vicki Brower | April 1, 2015 BUILDING A BETTER T-CELL: […]

First Success With CAR T-Cells in a Solid Tumor

Chimeric antigen-receptor (CAR) T-cell therapy has repeatedly provided dramatic results in patients with hematologic malignancies. Now comes the first success story of CAR T-cell therapy in a solid tumor — […]

CAR T-CELL BIOTECH IPOs

Company Date Value Kite Pharma June 2014 $134.1 million Bellicum December 2014 $160 million Juno December 2014 $264.6 million Cellectis March 2015 $228 million  

CAR T-CELL DEALS

Institution/Company Date Partner Terms University of Pennsylvania August 2012 Novartis Undisclosed Celgene March 2013 Bluebird Bio, Baylor College of Medicine Unspecified upfront payment plus up to $225 million per product […]

AAV9 VRs and their reported functional roles

AAV9 VRs and their reported functional roles.  Refer to http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3393551 VR AAV9 aa Reported functional role(s) References VR-I 262–269 Unknown in AAV9 VR-II 327–332 DE loop at the 5-fold channel; […]